




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/00		A2	(11) International Publication Number: WO 00/15210
			(43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21003		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 14 September 1999 (14.09.99)			
(30) Priority Data: 60/100,144 14 September 1998 (14.09.98) US 60/138,429 10 June 1999 (10.06.99) US			
(71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): TUNG, Roger [US/US]; 54 Richfield Road, Arlington, MA 01274 (US). KWONG, Ann [US/US]; 45 Sunset Road, Cambridge, MA 02138 (US).			
(74) Agents: HALEY, James, F. Jr.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US) et al.		<p>Published</p> <p>Without international search report and to be republished upon receipt of that report.</p>	

(54) Title: METHODS OF TREATING VIRAL DISEASE

Effect of MPA on Hepatitis B Virus Replication in HepG2 2.2.15 Cells



(57) Abstract

The invention relates to methods of treating viral diseases caused by viruses of the family *Flaviviridae*, or by a virus which targets the mammalian liver as a main repository for viral replication. The methods of this invention involve the use of mycophenolic acid or its derivatives, particularly mycophenolate mofetil alone, or in combination with other anti-viral agents. The methods of this invention are particularly useful in treating hepatitis B virus, hepatitis C virus, and dengue virus viral infections.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHODS OF TREATING VIRAL DISEASETECHNICAL FIELD OF THE INVENTION

The invention relates to methods of treating
5 viral diseases caused by viruses of the family
Flaviviridae, or by a virus which targets the mammalian
liver as a main repository for viral replication. The
methods of this invention involve the use of mycophenolic
acid or its derivatives, particularly mycophenolate
10 mofetil alone, or in combination with other anti-viral
agents. The methods of this invention are particularly
useful in treating hepatitis B virus, hepatitis C virus,
and dengue virus viral infections.

BACKGROUND OF THE INVENTION

15 Viral infections caused by virus of the family
Flaviviridae and viral diseases which target the
mammalian liver as the main site of viral replication
both present a great health risk to humans around the
world.

20 A virus which falls into both categories,
hepatitis C virus ("HCV"), is a major world health
problem. HCV infection causes about 10,000 deaths per
year. It is estimated that at least 4 million Americans
are infected with HCV -- 2 percent of the population.
25 Presently there is no cure for the disease and treatments
have just begun to be available.

Hepatitis B virus is an example of a prevalent
viral disease which targets the liver. Although a

vaccine is currently available, it is of questionable utility in individuals who are chronically infected with HBV.

Dengue is an example of a virus of the family
5 *Flaviviridae*. Dengue is not as prevalent as HBV or HCV,
but is known to break out in large epidemics in warmer
climates. Dengue fever is an acute infectious
disease caused by the flavivirus (a small RNA virus
related to yellow fever, tick-borne encephalitis, St
10 Louis encephalitis, and Japanese encephalitis) which is
transmitted by infected mosquitoes. The disease causes
headache, fever, muscle pain and rash, but is rarely
fatal.

However, a more severe form of the disease seen
15 mostly in children, dengue hemorrhagic fever, causes
severe symptoms including fever, shock, hemorrhaging from
the nose and mouth, respiratory distress and death.
Currently there is no treatment for dengue.

Mycophenolic acid ("MPA"), a naturally
20 occurring antibiotic produced by *Penicillium*
brevicompactum, and its derivatives including
mycophenolate mofetil ("MMF"; the morpholinoethyl ester
of MPA), have recently been described as
immunosuppressant drugs. In fact, the Food and Drug
25 Administration recently approved MMF for use in
preventing kidney transplant rejection.

Numerous derivatives of MPA and MMF, their
synthesis and use in treating various diseases are
described in United States Patents 4,686,234; 4,725,622;
30 4,727,069; 4,748,173; 4,753,935; 4,786,637; 4,808,592;
4,861,776; 4,948,793; 4,952,579; 4,959,386; 4,992,467;
5,247,083; 5,380,879; 5,441,953; 5,444,072; 5,493,030;

5,512,568; 5,525,602; 5,536,747; 5,538,969; 5,554,612;
and 5,633,279.

Although, several of the above-identified patents have suggested that MPA, MMF and its derivatives may be useful as anti-viral agents, the viral targets mentioned fall into either the retroviral or the Herpes virus class. Nowhere is there any teaching or suggestion that MPA, MMF and their derivatives would be useful in treating diseases that target the mammalian liver, in particular hepatitis B virus, hepatitis C virus, and dengue virus.

Viral diseases that target the mammalian liver are often widespread and severe. This, coupled with the lack of effective treatment for a subset of these diseases, places a great need on developing new avenues for treatment.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts the effect of varying concentrations of MPA on the amount of virion-associated hepatitis B virus DNA present in HepG2-2.2.15 cells and on cell death.

SUMMARY OF THE INVENTION

Applicants have solved the problem set forth above by discovering that MPA, MMF and their derivatives are surprisingly and unexpectedly useful in treating flavivirus infections and infections caused by virus that use the mammalian liver as their main site for replication.


The use of these well-known compounds alone, or in conjunction with one or more other anti-viral agents,

such as interferons, ribavirin, or inhibitors of viral life cycles (such as protease inhibitors, nucleoside analogs, inhibitors of other viral enzymes necessary for viral replication and infection) provides a method for
5 treating such viral diseases.


DETAILED DESCRIPTION OF THE INVENTION

According to one embodiment, the present invention provides a method of treating a mammal suffering from a viral disease caused by a member of the
10 family *Flaviviridae* or a viral disease of the liver, wherein said method comprises the step of administering to said mammal an amount of a compound selected from mycophenolic acid, mycophenolate mofetil, or a derivative of either of these compounds effective to lessen the
15 severity of said viral disease, wherein said compound is in a pharmaceutically acceptable composition.

Mycophenolic acid has the structure:



Mycophenolate mofetil has the structure:



20

Derivatives of these two compounds have been well-described in the literature. For example, 4-amino derivatives of mycophenolic acid are described in United

States Patents 5,380,879 and 5,441,953, and in PCT publication WO 95/22535. Mycophenolic acid derivatives containing a 5-substitution are described in United States Patents 5,493,030 and 5,633,279, and in PCT publication WO 95/22538. Mycophenolic acid derivatives containing a 6-substitution are described in United States Patents 5,444,072 and 5,536,747, as well as in PCT publication WO 95/22536. 4-amino derivatives of mycophenolic acid which contain a 5- or a 6-substitution are described in United States Patents 5,538,969, and 5,554,612, and in PCT publications WO 95/22537 and WO 95/22534. The disclosures of each of the above-cited patents and publications are herein incorporated by reference.

Any of the above-described compounds are useful in the methods of this invention. Preferably, the compound used is mycophenolate mofetil.

The term "viral diseases of the liver" as used herein, means a disease whose causative agent is a virus, wherein the virus targets the mammalian liver as its primary site of replication. Such viruses include, but are not limited to, hepatitis B virus, hepatitis C virus, hepatitis D virus, and hepatitis E virus. Examples of virus from the family *Flaviviridae* may be treated according to this invention are dengue and hepatitis C virus. According to a preferred embodiment, the methods of this invention are used to treat a hepatitis C virus infection.

The efficacy of the methods of this invention may be measured by observing how the treatment lessens the severity of the viral infection. This may be measured by various means. For example, a reduction in

the viral titer in the blood is considered to be a lessening of the severity of infection. Similarly, a decrease in the amount of an enzymatic activity associated with the virus (e.g., viral protease activity; viral helicase activity; viral polymerase activity) or a reduction in the presence of viral proteins may be taken as a measure of efficacy.

Another parameter is a sustained improvement in the patients health and well-being. This may be measured by a reduction or elimination of symptoms associated with the viral infection. One specific measure that may be used is the concentration of liver transaminases, particularly ALT and AST, found in the patient's plasma. It may also be measured, in a human being, by interviewing the patient.

A pharmaceutically acceptable composition according to this invention is one in which the compound is formulated together with a pharmaceutically acceptable carrier for administration to a mammal.

Pharmaceutically acceptable carriers that may be used in these compositions include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes,

polyethylene-polyoxypropylene-block polymers,
polyethylene glycol and wool fat.

According to a preferred embodiment, the
compositions of this invention are formulated for
5 pharmaceutical administration to a human being.

Such pharmaceutical compositions of the present
invention may be administered orally, parenterally, by
inhalation spray, topically, rectally, nasally, buccally,
vaginally or via an implanted reservoir. The term
10 "parenteral" as used herein includes subcutaneous,
intravenous, intramuscular, intra-articular, intra-
synovial, intrasternal, intrathecal, intrahepatic,
intralesional and intracranial injection or infusion
techniques. Preferably, the compositions are
15 administered orally.

Sterile injectable forms of the compositions of
this invention may be aqueous or oleaginous suspension.
These suspensions may be formulated according to
techniques known in the art using suitable dispersing or
20 wetting agents and suspending agents. The sterile
injectable preparation may also be a sterile injectable
solution or suspension in a non-toxic parenterally-
acceptable diluent or solvent, for example as a solution
in 1,3-butanediol. Among the acceptable vehicles and
25 solvents that may be employed are water, Ringer's
solution and isotonic sodium chloride solution. In
addition, sterile, fixed oils are conventionally employed
as a solvent or suspending medium. For this purpose, any
bland fixed oil may be employed including synthetic mono-
30 or di-glycerides. Fatty acids, such as oleic acid and
its glyceride derivatives are useful in the preparation
of injectables, as are natural pharmaceutically-

acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as Ph. Helv or
5 similar alcohol.

The pharmaceutical compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In
10 the case of tablets for oral use, carriers which are commonly used include lactose and corn starch. Lubricating agents, such as magnesium stearate, are also typically added. For oral administration in a capsule
15 form, useful diluents include lactose and dried corn starch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

Alternatively, the pharmaceutical compositions
20 of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient which is solid at room temperature but liquid at rectal temperature and therefore will melt
25 in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

The pharmaceutical compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs
30 readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal

tract. Suitable topical formulations are readily prepared for each of these areas or organs.

Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

For topical applications, the pharmaceutical compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, the pharmaceutical compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

For ophthalmic use, the pharmaceutical compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the pharmaceutical compositions may be formulated in an ointment such as petrolatum.

The pharmaceutical compositions of this invention may also be administered by nasal aerosol or

inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

Various pharmaceutical formulations of MPA, MMF and their derivatives have been described in United States Patent 5,455,045; 5,543,408; 5,554,384 and 5,688,529, the disclosures of which are herein incorporated by reference. These formulations, in particular the high dose oral suspensions of MMF described in United States Patent 5,688,529, are preferred in the methods of the present invention.

In a preferred embodiment, the MPA, MMF or a derivative thereof is administered together with at least one other anti-viral agent.

Other anti-viral agents useful in this embodiment include, but are not limited to, α -interferons, β -interferons, γ -interferons, viral protease inhibitors, ribavirin, viral helicase inhibitors, viral polymerase inhibitors, antibodies to viral surface proteins, and antibodies to viral core proteins.

Preferably, the other anti-viral agent used in the methods of this invention is an α -interferon, which is optionally modified by conjugating with polyethylene glycol ("pegylation").

The other anti-viral agent may be administered as part of a single dosage combination with MPA, MMF or a derivative thereof. Alternatively, the other anti-viral agent may be administered as a separate dosage form.

When used as a separate dosage form the other anti-viral agent may be administered prior to, simultaneously with, or following administration of MPA, MMF or a derivative thereof.

5 Daily dosages of MPA, MMF or derivatives thereof utilized in the methods of this invention should be between about 0.01 to 100.0 mg/kg body weight, preferably between about 0.1 to 70 mg/kg of body weight. If other anti-viral agents are present, they should be
10 administered at daily dosages of between about 70 to 100% of the dosage normally administered when that agent is used in a monotherapy.

 The amount of active compound administered will, of course, be dependent upon a number of factors,
15 including the sex of the mammal, the nature and severity of the viral infection, the route and schedule of the administration and the judgment of the prescribing physician.

 In order that this invention be more fully
20 understood, the following examples are set forth. These examples are for the purpose of illustration only and are not to be construed as limiting the scope of the invention in any way.

25

EXAMPLE 1

Effect of MPA on Hepatitis B Virus Infection

 We plated HepG2-2.2.15 cells in 96-well
microtiter plates at an initial density of 2.5×10^3
cells/100 μ l in DMEM medium supplemented with 10% fetal
30 bovine serum. To promote cell adherence, the 96-well plates were pre-coated with collagen prior to cell plating. After incubation at 37°C in a humidified, 5% CO₂

environment for 16-24 hours, the confluent monolayer of HepG2-2.2.15 cells was washed, and the medium was replaced with complete medium containing various concentrations of MPA (0 to 31 μ M). On day three, the culture medium was replaced with fresh medium containing the same amount of MPA. Six days following the initial administration of MPA, the cell culture supernatant was collected and clarified by centrifugation (Sorvall RT-6000D centrifuge, 1000 rpm for 5 min).

Samples were then treated with 0.75 mg/ml Pronase for 30 minutes at 37°C and 1 unit DNase for 60 minutes at 37°C to inactivate proteases and degrade any unencapsidated viral DNA. The DNase present in the samples was inactivated by heating the samples to 95°C for 30 minutes. Three microliters of clarified supernatant was then subjected to real-time quantitative PCR using conditions described below.

Virion-associated HBV DNA present in the tissue culture supernatant was PCR amplified using primers derived from HBV strain ayw. PCR-amplified HBV DNA was detected in real-time (i.e., at each PCR thermocycle step) by monitoring increases in fluorescence signals that result from exonucleolytic degradation of a quenched fluorescent probe molecule following hybridization of the probe to the amplified HBV DNA. The TaqMan probe molecule, designed with the aid of Primer Express™ (PE-Applied Biosystems) software, is complementary to DNA sequences present in the HBV DNA region.

Routinely, 3 μ l of clarified supernatant was analyzed directly (without DNA extraction) in a 50 μ l PCR reaction. Reagents and conditions used are per the manufacturers suggestions (PE-Applied Biosystems). For

each PCR amplification, a standard curve was simultaneously generated from several log dilutions of a purified 1.2 kbp HBV ayw subgenomic fragment. Routinely, the standard curve ranged from 1×10^6 to 1×10^1 nominal copy equivalents per PCR reaction.

The results of this assay are shown in Figure 1. Figure 1 demonstrates that there is a linear decrease in the amount of HBV DNA detected with increasing amounts of MPA administered up to 0.488 μM . Above 0.488 μM , the cells begin to die and therefore the further linear decrease in HBV DNA is difficult to interpret. This assay demonstrates that MPA is effective in reducing hepatitis B viral titer in infected cells. Infections caused by other virus of the *Flaviviridae* family and other virus that target the liver of a mammal as the major site of replication will also be reduced in severity by treatment with MPA.

While we have hereinbefore presented a number of embodiments of this invention, it is apparent that our basic construction can be altered to provide other embodiments which utilize the methods of this invention. Therefore, it will be appreciated that the scope of this invention is to be defined by the claims appended hereto rather than the specific embodiments which have been presented hereinbefore by way of example.

CLAIMS

We claim:

1. A method of treating a mammal suffering from a disease caused by a virus of the family *Flaviviridae* or by a virus that targets the liver of said mammal as the major site of replication, said method comprising the step of treating said mammal with a pharmaceutical composition comprising:

a. an amount of a compound selected from mycophenolic acid, mycophenolate mofetil, or a derivative thereof effective to decrease the severity of said disease; and

b. a pharmaceutically acceptable carrier.

2. The method according to claim 1, wherein said mammal is additionally administered an additional antiviral agent, wherein said antiviral agent is formulated together with said compound in single dosage form or wherein said antiviral agent is administered to said mammal as a separate dosage form.

3. The method according to claim 2, wherein said additional antiviral agent is selected from an α -interferon or a pegylated α -interferon.

4. The method according to any one for claims 1 to 3, wherein said mammal is suffering from a disease caused by a virus selected from hepatitis B virus, hepatitis C virus, hepatitis D virus, hepatitis E virus,


or dengue virus.

5. The method according to claim 4, wherein said virus is hepatitis C virus and said mammal is a human.

6. The method according to claim 1 or 5, wherein said pharmaceutical composition is formulated for oral administration.

1/1

Effect of MPA on Hepatitis B Virus Replication in HepG2 2.2.15 Cells



PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/365, 38/21	A3	(11) International Publication Number: WO 00/15210 (43) International Publication Date: 23 March 2000 (23.03.00)
(21) International Application Number: PCT/US99/21003 (22) International Filing Date: 14 September 1999 (14.09.99) (30) Priority Data: 60/100,144 14 September 1998 (14.09.98) US 60/138,429 10 June 1999 (10.06.99) US (71) Applicant (for all designated States except US): VERTEX PHARMACEUTICALS INCORPORATED [US/US]; 130 Waverly Street, Cambridge, MA 02139-4242 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): TUNG, Roger [US/US]; 54 Richfield Road, Arlington, MA 01274 (US). KWONG, Ann [US/US]; 45 Sunset Road, Cambridge, MA 02138 (US). (74) Agents: HALEY, James, F. Jr.; Fish & Neave, 1251 Avenue of the Americas, New York, NY 10020 (US) et al.		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> (88) Date of publication of the international search report: 25 May 2000 (25.05.00)
(54) Title: USE OF MYCOPHENOL ACID AND ITS DERIVATIVES FOR THE TREATMENT OF VIRUS DISEASES (57) Abstract The invention relates to methods of treating viral diseases caused by viruses of the family <i>Flaviviridae</i> , or by a virus which targets the mammalian liver as a main repository for viral replication. The methods of this invention involve the use of mycophenolic acid or its derivatives, particularly mycophenolate mofetil alone, or in combination with other anti-viral agents. The methods of this invention are particularly useful in treating hepatitis B virus, hepatitis C virus, and dengue virus viral infections.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21003

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/365 A61K38/21

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 688 529 A (HEGDE SAYEE GOJANAN ET AL) 18 November 1997 (1997-11-18) cited in the application	1,6
Y	column 12, line 54,61; claims column 13, line 39	2-5
X	US 5 444 072 A (PATTERSON JOHN W ET AL) 22 August 1995 (1995-08-22) cited in the application column 1, line 68 column 66, line 27,28 column 66, line 35,36 column 67, line 15,16	1,6
Y	WO 97 16204 A (SCHERING CORP) 9 May 1997 (1997-05-09) claims; examples	2-5

-/-

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

13 March 2000

Date of mailing of the international search report

20/03/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Veronese, A

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 99/21003

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,Y	WO 98 48840 A (SCHERING CORP) 5 November 1998 (1998-11-05) the whole document	2-5
X	GONG, Z. J. ET AL: "Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in cultures of primary and immortalized human hepatocytes." HEPATOLOGY, (1997) VOL. 26, NO. 4 PART 2, PP. 226A. MEETING INFO.: 48TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR THE STUDY OF LIVER DISEASES CHICAGO, ILLINOIS, USA NOVEMBER 7-11, 1997 , XP000889646 the whole document	1,4-6
X	PLATZ K P ET AL: "Indications for mycophenolate mofetil therapy in hepatitis C-patients undergoing liver transplantation." TRANSPLANTATION PROCEEDINGS, (1998 JUN) 30 (4) 1468-9. , XP000889647 page 1469, column 1-2	1,4-6
X	PLATZ K P ET AL: "Indication for mycophenolate mofetil therapy in hepatitis C patients undergoing liver transplantation." TRANSPLANTATION PROCEEDINGS, (1998 AUG) 30 (5) 2232-3. , XP000889658 page 2233, column 2	1,4-6
X	GONG, Z. J. (1) ET AL: "Differential anti - hepatitis B virus activity in vitro of three potent of inosine monophosphate dehydrogenase inhibitors: Mycophenolic acid (MPA), 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and ribavirin." JOURNAL OF HEPATOLOGY, (1998) VOL. 28, NO. SUPPL. 1, PP. 103. MEETING INFO.: 33RD ANNUAL MEETING OF THE EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER LISBON, PORTUGAL APRIL 15-18, 1998 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER. , XP000889851 the whole document	1,4-6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/21003

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim(s) 1-6
is(are) directed to a method of treatment of the human/animal
body, the search has been carried out and based on the alleged
effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such
an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all
searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment
of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report
covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is
restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 99/21003

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 5688529	A	18-11-1997	AU 678303 B	22-05-1997
			AU 7920594 A	01-05-1995
			BR 9407728 A	12-02-1997
			CA 2172506 A	13-04-1995
			CN 1132479 A	02-10-1996
			CZ 9600954 A	12-06-1996
			EP 0721335 A	17-07-1996
			FI 961466 A	01-04-1996
			HU 73675 A	30-09-1996
			IL 111116 A	05-04-1998
			JP 9509648 T	30-09-1997
			LT 96039 A, B	25-10-1996
			LV 11428 A	20-08-1996
			LV 11428 B	20-12-1996
			NO 961325 A	01-04-1996
			NZ 274678 A	29-07-1999
			PL 313772 A	22-07-1996
			SG 55007 A	21-12-1998
			SI 9420057 A	31-10-1996
			WO 9509626 A	13-04-1995
			ZA 9407683 A	01-04-1996
US 5444072	A	22-08-1995	AU 1917095 A	04-09-1995
			BR 9506835 A	14-10-1997
			CA 2183533 A	24-08-1995
			CN 1141040 A	22-01-1997
			EP 0745075 A	04-12-1996
			FI 963221 A	16-10-1996
			HR 950071 A	30-06-1997
			JP 9509172 T	16-09-1997
			WO 9522536 A	24-08-1995
			US 5536747 A	16-07-1996
			ZA 9501295 A	16-08-1996
WO 9716204	A	09-05-1997	AU 7473096 A	22-05-1997
			CA 2236591 A	09-05-1997
			EP 0858343 A	19-08-1998
			US 5908621 A	01-06-1999
WO 9848840	A	05-11-1998	US 5908621 A	01-06-1999
			AU 7249098 A	24-11-1998
			EP 0975369 A	02-02-2000
			NO 995263 A	27-12-1999
			ZA 9803543 A	10-11-1998